» Articles » PMID: 6141201

TSH-displacing Activity Versus TSH-binding Inhibiting Activity of Immunoglobulins from Patients with Graves' Disease

Overview
Publisher Springer
Specialty Endocrinology
Date 1983 Oct 1
PMID 6141201
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of binding of TSH to thyroid plasma membranes by immunoglobulins G (IgG) from patients with Graves' disease has been interpreted as evidence of an interaction with the TSH receptor, but other explanations may account for this phenomenon. Displacement of receptor-bound TSH might be a more direct index of such an interaction. The aim of the present study was to assess TSH-displacing activity (TDA) of Graves' IgG by a newly developed assay and compare TDA to TSH-binding inhibiting activity (TBIA) and thyroid-stimulating antibody (TSAb) activity. TDA was assessed by preincubating 125I-TSH with thyroid plasma membranes and by measuring residual bound 125I-TSH after addition of IgG. TBIA was evaluated by determining binding of 125I-TSH to thyroid plasma membranes preincubated with IgG. Results were expressed as % TSH-displacing or binding inhibition activities of test IgG with respect to normal control IgG. The percent of TDA positive Graves' IgG preparations (72.7%) was greater than that of TBIA positive (48.5%). There was no correlation between TDA and TBIA results, since 11 Graves' IgG preparations were TDA positive but TBIA negative, and 6 were TDA negative but TBIA positive. Hashimoto's or idiopathic myxedema IgG preparations were positive in 2/7 in the TDA and in 1/7 in the TBIA assays, respectively. Neither TDA nor TBIA correlated with TSAb determined by cAMP accumulation in thyroid plasma membrane. The TDA assay developed in this study appeared to be more sensitive than the more widely used TBIA assay.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Peripheral blood mononuclear cells - Can they provide a clue to the pathogenesis of Graves' Orbitopathy?.

Basak M, Sanyal T, Kar A, Bhattacharjee P, Das M, Chowdhury S Endocrine. 2021; 75(2):447-455.

PMID: 34545512 DOI: 10.1007/s12020-021-02865-0.


Increased generation of fibrocytes in thyroid-associated ophthalmopathy.

Douglas R, Afifiyan N, Hwang C, Chong K, Haider U, Richards P J Clin Endocrinol Metab. 2009; 95(1):430-8.

PMID: 19897675 PMC: 2805489. DOI: 10.1210/jc.2009-1614.

References
1.
Hall R, Smith B, Mukhtar E . Thyroid stimulators in health and disease. Clin Endocrinol (Oxf). 1975; 4(2):213-30. DOI: 10.1111/j.1365-2265.1975.tb01529.x. View

2.
Endo K, Kasagi K, Konishi J, Ikekubo K, Okuno T, Takeda Y . Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1978; 46(5):734-9. DOI: 10.1210/jcem-46-5-734. View

3.
Sugenoya A, Kidd A, Row V, Volpe R . Correlation between thyrotropin-displacing activity and human thyroid-stimulating activity by immunoglobulins from patients with Graves' disease and other thyroid disorders. J Clin Endocrinol Metab. 1979; 48(3):398-402. DOI: 10.1210/jcem-48-3-398. View

4.
ODonnell J, Trokoudes K, Silverberg J, Row V, Volpe R . Thyrotropin displacement activity of serum immunoglobulins from patients with Graves' disease. J Clin Endocrinol Metab. 1978; 46(5):770-7. DOI: 10.1210/jcem-46-5-770. View

5.
Fenzi G, Macchia E, Bartalena L, Mazzanti F, BASCHIERI L, DeGroot L . Radio-receptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins. J Endocrinol Invest. 1978; 1(1):17-24. DOI: 10.1007/BF03346766. View